Health Care · Pharmaceutical Preparations

PTGX Protagonist Therapeutics, Inc SEC Filings & Insider Trading Activity 2026

company
CIK 1377121120 filings
Russell 2000

PTGX at a glance

Protagonist Therapeutics, Inc (PTGX, SEC CIK 1377121) filed its latest 10-K annual report on February 25, 2026, a 10-Q quarterly report on November 6, 2026, an 8-K current report on November 5, 2026 and Form 4 insider filings as recently as November 20, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), Protagonist Therapeutics, Inc (PTGX) reported revenue of $46.0 million (down 89.4% from FY2024) and a net loss of $130.1 million. Diluted EPS was -$2.05.
  • As of September 30, 2026, 30 institutional investment managers tracked by SignalX reported holding Protagonist Therapeutics, Inc (PTGX) shares worth $4.8 billion in 13F-HR filings.
  • The most recent insider open-market sale reported on Form 4 was by MOLINA ARTURO MD on November 16, 2026 of 2,718 shares at $124.65 per share.
  • In the last 90 days, PTGX insiders reported 0 open-market purchases ($0) and 6 open-market sales ($26.9M) on Form 4, a net sale of $26.9M.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$46.0M
−89.4% vs prior year
Insiders · 90 days
0 buys · 6 sells
Net −$26.9M
13F holders
30 funds
$4.8B · +2 vs prior quarter
Latest 8-K
Nov 5, 2026
Item 2.02

AI 10-K Annual Report Analysis

Latest 10-K, fiscal year ended Dec 31, 2025

Full analysis →

Business Overview

  • Core business: Development and commercialization of pharmaceutical and biological products subject to extensive U.S. and EU regulatory oversight
  • New filings: July 2025 NDA by Johnson & Johnson for Icotyde; January 2026 NDA by Protagonist and Takeda for rusfertide for polycythemia vera
  • Strategic focus: Emphasis on global clinical trials and international marketing with associated geopolitical and regulatory risk exposure
  • Quantitative metric: Introduction of new U.S. tariffs up to 100% on branded pharmaceuticals announced September 2025, potential cost impact
  • Noteworthy fact: May 2025 executive order on most-favored-nation drug pricing aiming to align U.S. prices with OECD countries affecting pricing strategy

Risk Factors

  • Regulatory risk: FDA approval timing and receipt of up to $400M payments plus $75M milestone under Takeda Collaboration Agreement opt-out in 2026
  • Macroeconomic risk: exposure to geopolitical instability, high interest rates, and trade policy changes potentially impacting operations and FDA agency functioning
  • Operational risk: reliance on third-party clinical trial sites and contract manufacturers with accrual variability affecting R&D expense accuracy
  • Market disruption risk: competition in obesity and oral hepcidin therapy markets with development of PN-477, PN-458, and PN-8047 pipeline candidates
  • Financial risk: cumulative net losses of $470.7M through 2025 with increased R&D expenses of $159.3M, pressuring liquidity and funding needs

Management Discussion & Analysis

  • Revenue not explicitly disclosed; milestone payments: $165M (2025), $300M upfront (2024), $25M milestone (2025)
  • Net loss $130.1M in 2025 vs net income $275.2M in 2024; no margin % figures provided
  • Cash from operations $57.7M (2025) down from $184.2M (2024), driven by milestone-related cash flows
  • Cash flow investing: $49.3M (2025) vs $299.5M (2024) used, mainly marketable securities transactions and capex $1.6M (2025)
  • Financing cash inflows $22.9M (2025) vs $25.9M (2024) from stock issuances; $0 buybacks or dividends mentioned
  • Outlook: Cash $646M sufficient for at least 12 months; potential future funding needs depend on pipeline advancement and collaborations

AI summary of the PTGX 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Risk Factors

  • No material changes from the December 31, 2025 Form 10-K risk factors
  • Carried-forward business risk: risks described throughout the September 30, 2026 Form 10-Q and other SEC filings
  • Prior-quarter changes: risks identified in the June 30, 2026 Form 10-Q remain the latest updates

Management Discussion & Analysis

  • Revenue $274.4M, up from $4.7M YoY, primarily from Takeda opt-out and milestone payments
  • Net income $220.0M vs $39.3M loss YoY, operating margin 79.6% vs negative 985.0%
  • PN-881 R&D $10.4M, strongest clinical program; MIMRYLO R&D $3.2M, down 85% YoY
  • Cash, equivalents and securities $834.6M vs $646.0M at December 31, 2025; operating cash flow $146.9M
  • $5.8M stock repurchases; R&D spending expected to rise for PN-881, PN-477o, PN-458 and PN-8047 development

AI summary of the PTGX 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 5, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Third-quarter 2026 financial results for period ended September 30, 2026
  • Corporate update announced alongside quarterly results

Item EX-99.1: Item EX-99.1

  • MIMRYLO FDA approval triggered $275 million in Takeda payments, materially strengthening near-term liquidity and validating the partnered-asset strategy
  • Cash, equivalents and marketable securities reached $834.6 million, supporting pipeline investment and the authorized $300 million share repurchase
Filed Aug 5, 2026Full analysis →

Item 7.01: Regulation FD Disclosure

  • Updated corporate presentation furnished August 5, 2026 under Regulation FD
  • Investor-relevant information resides in Exhibit 99.2, potentially covering pipeline and corporate developments

Item 2.02: Results of Operations and Financial Condition

  • Q2 2026 results reported for quarter ended June 30, 2026
  • Corporate update accompanies earnings release in Exhibit 99.1

Item EX-99.1: Item EX-99.1

  • Q2 revenue $213.5M, primarily $192.4M Takeda opt-out recognition; reported net income $162.8M versus $34.8M loss
  • Cash, equivalents and marketable securities $849.5M, up from $646.0M at December 31, 2025

Item EX-99.2: Item EX-99.2

  • Presentation highlights $912.5M earned partnership payments through June 2026, supporting internally funded pipeline development
  • ICOTYDE FDA approved in March 2026, with 6% to 10% royalties and $580M future milestones from J&J
Filed Jun 18, 2026Full analysis →

Item 5.02: Departure/Appointment of Directors or Principal Officers

  • Stockholders approved the 2026 Equity Incentive Plan, replacing the 2016 Plan
  • Plan adds 650,000 new shares plus recycling of certain unused or forfeited 2016 Plan awards

Item 5.07: Submission of Matters to a Vote of Security Holders

  • Two Class I directors, Dinesh V. Patel and Lewis T. Williams, elected through 2029
  • Executive compensation approved on advisory basis, with 53,412,559 votes for

AI summaries of PTGX 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for PTGX

Don't miss the next PTGX filing

  • Alerts as it files. A push when PTGX files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut PTGX, by share count.
  • Ask anything. An AI agent that reads every PTGX filing and answers with sources.

PTGX alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
PATEL DINESH V PH DGNov 19, 2026-
MOLINA ARTURO MDSellNov 16, 2026$124.65
Ali AsifMSep 30, 2026-
Ali AsifMSep 30, 2026-
Ali AsifMSep 30, 2026$19.19
Ali AsifSellSep 30, 2026$141.78
Ali AsifMSep 30, 2026$23.42
Ali AsifMSep 30, 2026$12.17

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue-$434.4M$46.0M
Operating Income-$252.8M-$158.1M
Net Income-$79.0M$275.2M-$130.1M
Op. Margin-58.2%-343.6%
Net Margin-63.3%-282.8%
Balance Sheet
Total Assets-$744.7M$668.2M
Equity$336.7M$675.3M$614.7M
ROE-23.5%40.8%-21.2%
Per Share
EPS$-1.39$4.23$-2.05
Cash Flow
Operating CF-$184.2M$57.7M
CapEx$609K$1.4M$1.6M

Source: XBRL data in Protagonist Therapeutics, Inc (PTGX)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate PTGX share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
PTGX shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202630$4.79B
Q2 202628$4.14B
Q1 202629$3.53B
Q4 202529$2.69B
Q3 202528$1.89B
Q2 202529$1.53B
Q1 202529$780.1M
Q4 202425$557.6M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 227 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

PTGX filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
4Nov 20, 2026--
4Nov 17, 2026--
10-QNov 6, 2026Analysis
8-KNov 5, 2026Analysis-
4Oct 2, 2026--
4Sep 10, 2026--
4Sep 8, 2026--
4Aug 12, 2026--
SC 13GAug 7, 2026-
10-QAug 5, 2026Analysis
8-KAug 5, 2026Analysis-
4Jun 25, 2026--
8-KJun 18, 2026Analysis-
4Jun 11, 2026--
4Jun 1, 2026-
SC 13GMay 12, 2026-
4May 12, 2026-
4May 11, 2026-
8-KMay 5, 2026Analysis-
10-QMay 5, 2026Analysis
SC 13GApr 30, 2026-
SC 13GApr 29, 2026-
4Apr 24, 2026--
4Apr 21, 2026--
4Mar 27, 2026--

Related Health Care companies

All Health Care →

PTGX SEC filings: frequently asked questions

Are PTGX insiders buying or selling?

In the last 90 days, Protagonist Therapeutics, Inc (PTGX) officers, directors and 10% owners reported no open-market purchases and 6 open-market sales worth $26.9 million by 3 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.

Which institutions hold PTGX stock?

As of September 30, 2026, the largest Protagonist Therapeutics, Inc (PTGX) holders among the 13F filers tracked by SignalX were BlackRock ($1.5 billion), Vanguard Portfolio Management LLC ($516.9 million), State Street Corp ($490.2 million), Vanguard Capital Management LLC ($407.9 million), Invesco Ltd ($399.7 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was PTGX's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), Protagonist Therapeutics, Inc (PTGX) reported revenue of $46.0 million (down 89.4% from FY2024) and a net loss of $130.1 million. Diluted EPS was -$2.05. The figures come from the XBRL data in the 10-K.

What are the main risks in PTGX's latest 10-K?

In the 10-K filed February 25, 2026, Protagonist Therapeutics, Inc (PTGX) flagged: Regulatory risk: FDA approval timing and receipt of up to $400M payments plus $75M milestone under Takeda Collaboration Agreement opt-out in 2026. Macroeconomic risk: exposure to geopolitical instability, high interest rates, and trade policy changes potentially impacting operations and FDA agency functioning. (AI summary of the Risk Factors section.)

What did PTGX report in its latest 8-K?

Protagonist Therapeutics, Inc (PTGX) filed an 8-K on November 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Third-quarter 2026 financial results for period ended September 30, 2026.

What are the latest PTGX SEC filings?

Protagonist Therapeutics, Inc (PTGX) filed its latest 10-K annual report on February 25, 2026, a 10-Q quarterly report on November 6, 2026, an 8-K current report on November 5, 2026 and a Form 4 insider filing on November 20, 2026.

What is PTGX's SEC CIK number?

Protagonist Therapeutics, Inc (PTGX)'s SEC Central Index Key (CIK) is 1377121. EDGAR lists every PTGX filing under that number.

Ask anything about PTGX

The research agent reads PTGX's filings, financials, insider trades and 13F holders, then answers with sources.